Combination of finasteride and flutamide as potency-sparing hormone ablation therapy in management of advanced carcinoma of prostate

• Main Authors: N K Mohanty, R P Arora, A K Jha, Sujeet Kumar
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2001-01-01
• Series: Indian Journal of Urology
• Subjects: α-Reductase Inhibitor; Potency: Hormone: Flutamide; Finasteride.
• Online Access: http://www.indianjurol.com/article.asp?issn=0970-1591;year=2001;volume=18;issue=1;spage=49;epage=51;aulast=Mohanty

Complete androgen blockade by LHRH agonist /Orchiectomy plus antiandrogen results in androgen deficiency amongst males (ADAM). We treated advanced cancer prostate with finasteride and flutamide with an aim of potency sparing in relatively younger males with the disease. 45 sexually active males between the age of 48 to 65 having advanced cancer of prostate were treated, for 1 year with Flutamide (750mg) and Finasteride (5mg) daily and followed up for 18 months. Results showed 89% having low PSA and 80% maintained their sexual potency. Side effects were mild: 20% of patients developing diarrhoea, gynaecomastia and hot flushes with good drug compliance. This combination is ideal as potency sparing androgen ablation therapy for advanced cancer of prostate among young & sexually active males.